AccuMed
This article was originally published in The Gray Sheet
Executive Summary
Acquires 1 mil. of Oncometrics Imaging Corp. common stock from Xillix Technologies Corp., making Oncometrics a wholly owned subsidiary of AccuMed. Xillix divested its Oncometrics stock in order to focus on developing its LIFE fluorescent endoscopy system platform for the early detection and localization of cancer. Terms of the transaction were not disclosed